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INTRODUCTION
Cancer is one of the leading causes of death worldwide. Cancer 
cells undergo rapid, uncontrolled proliferation, which makes the 
microenvironment to hypoxic condition, results in depleted the 
oxygen, and insufficient blood supply. To fulfill their demands 
for nutrient, oxygen, and other growth factors, angiogenesis is re-
quired. Several studies have revealed that targeting angiogenesis 
is an effective approach for cancer therapy under hypoxic condi-
tions [1,2]. However, the molecular mechanisms underlying this 
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ABSTRACT Tumor undergo uncontrolled, excessive proliferation leads to hypoxic mi-
croenvironment. To fulfill their demand for nutrient, and oxygen, tumor angiogenesis 
is required. Endothelial progenitor cells (EPCs) have been known to the main source 
of angiogenesis because of their potential to differentiation into endothelial cells. 
Therefore, understanding the mechanism of EPC-mediated angiogenesis in hypoxia 
is critical for development of cancer therapy. Recently, mitochondrial dynamics has 
emerged as a critical mechanism for cellular function and differentiation under hy-
poxic conditions. However, the role of mitochondrial dynamics in hypoxia-induced 
angiogenesis remains to be elucidated. In this study, we demonstrated that hypoxia-
induced mitochondrial fission accelerates EPCs bioactivities. We first investigated the 
effect of hypoxia on EPC-mediated angiogenesis. Cell migration, invasion, and tube 
formation was significantly increased under hypoxic conditions; expression of EPC 
surface markers was unchanged. And mitochondrial fission was induced by hypoxia 
time-dependent manner. We found that hypoxia-induced mitochondrial fission was 
triggered by dynamin-related protein Drp1, specifically, phosphorylated DRP1 at 
Ser637, a suppression marker for mitochondrial fission, was impaired in hypoxia time-
dependent manner. To confirm the role of DRP1 in EPC-mediated angiogenesis, we 
analyzed cell bioactivities using Mdivi-1, a selective DRP1 inhibitor, and DRP1 siRNA. 
DRP1 silencing or Mdivi-1 treatment dramatically reduced cell migration, invasion, and 
tube formation in EPCs, but the expression of EPC surface markers was unchanged. 
In conclusion, we uncovered a novel role of mitochondrial fission in hypoxia-induced 
angiogenesis. Therefore, we suggest that specific modulation of DRP1-mediated mi-
tochondrial dynamics may be a potential therapeutic strategy in EPC-mediated tumor 
angiogenesis.
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process remains unclear. 
Endothelial progenitor cells (EPCs) were first discovered and 
isolated by Asahara et al. in 1997 [3]. They found that EPCs have 
the ability to form new blood vessels in a process known as neo-
vascularization. EPCs can be isolated from CD34+ cells in human 
cord blood, peripheral blood, as well as the bone marrow. They 
express the surface markers for CD34, CD31, and vascular en-
dothelial growth factor receptor-2 (VEGFR-2, KDR) [4,5]. It has 
been established that EPCs contribute to tumor development and 
metastasis via tumor angiogenesis [6]. In addition, they demon-
strate the ability to differentiate into endothelial cells (EC), which 
is stimulated by pathological conditions such as hypoxia. Hypox-
ia-induced angiogenesis is consist of several successional steps in-
cluding 1) angiogenic factors (such as VEGF, bFGF) released from 
hypoxic cells, and bind to EC / EPC, 2) activate MMPs to degra-
date the extracellular membrane (ECM), then 3) cell migration 
and invasion, 4) tube formation, 5) vessel stabilization, in briefly. 
Therefore, understanding the mechanism of hypoxia-induced 
angiogenesis and finding a new approach to prevent angiogenic 
function are essential for development of cancer therapy. 
Recently, mitochondrial dynamics has emerged as a criti-
cal mechanism for cellular function in hypoxic cell signaling. 
Mitochondria are dynamic subcellular organelles that undergo 
continuous fission and fusion to maintain mitochondrial func-
tion and energy metabolism [7,8]. These processes are tightly 
regulated by specific molecules, such as dynamin-related protein 
Drp1 for fission, and MFN1/2 and OPA1 for fusion. Homeosta-
sis between mitochondrial fission and fusion is important for 
sustaining cell survival, proliferation, and differentiation. For 
example, mitochondrial fission induced by CDK1/cyclinB/pDRP1 
axis is essential for cell mitosis [9], and phosphorylation of DRP1 
at Ser637 induced by nutrient starvation sustain the cell survival 
via inhibition of mitochondrial fission [10]. Kasturi et al. reported 
that DRP1-dependent mitochondrial fission is essential for cell 
differentiation [11], Luchsinger et al. showed that MFN2-induced 
mitochondrial fusion plays critical role to maintain stem cells [12]. 
It has been well-established that a shift towards mitochondrial fis-
sion occurs under hypoxic conditions [13,14]. Most of the studies 
to date have focused on the relationship between mitochondrial 
fission, increased ROS production, and apoptosis [15,16]. A few 
reports have also investigated the effect of accelerated mitochon-
drial fission on cell migration and invasion in breast cancer [17]. 
However, little is known about the effect of mitochondrial fission 
on endothelial cells during angiogenesis. 
Therefore, the aim of this study is to clarify the role of mito-
chondrial fission in hypoxia-induced angiogenesis. This study 
demonstrated that specific inhibition of DRP1-mediated mito-
chondrial fission attenuated the EPC bioactivities under hypoxia. 
We suggest the regulation of mitochondrial dynamics maybe a 
novel therapeutic approach for cancer therapy.
METHODS
Isolation of endothelial progenitor cells
Human EPCs were isolated as previously described [18]. All 
experimental procedures have been reviewed and approved by 
the International Review Board (IRB) of Pusan National Univer-
sity Hospital (IRB No.05-2017-053). In brief, mononuclear cells 
(MNCs) were separated from human umbilical cord blood using 
Ficoll-Paque PLUS (GE Healthcare, Uppsala, Sweden), according 
to manufacturer’s instructions. MNCs were cultured with the 
EGM-2 Bullet Kit system (Lonza, Walkersville, MD, USA) for 
five days in 1% gelatin-coated plates. Cultures were supplemented 
with 1X penicillin streptomycin (Welgene, Korea). EPCs formed 
spindle-shaped colonies. To generate hypoxic conditions, cells 
were starved with 1% FBS in EBM-2 media for 12 h, followed by a 
24-h culture period at 1% O2. 
Cell viability assay
Mdivi-1 was obtained from Sigma Aldrich, and was dissolved 
in DMSO to yield a stock concentration of 5 mM. To assess cell 
viability, 1×105 EPCs were seeded in 96-well plates for 24 h. Fol-
lowing stabilization, EPCs were treated with serially diluted 
Mdivi-1 (0, 3.125, 6.25, 12.5, 25, 50, 100 mM) for 24 h. The effect of 
Mdivi-1 on cell viability was measured using D-Plus CCK cell vi-
ability assay kit (Dongin LS, Korea), according to manufacturer’s 
protocol. To quantify cell viability, absorbance was measured at 
450 nm with a TECAN microplate reader; results were normal-
ized and compared with those of the untreated control.
siRNA-mediated knockdown of DRP1 gene expression
DRP1 siRNA (siDRP1) was a kind gift from Prof. Young chan 
Chae (UNIST), and scramble siRNA (scRNA) was purchased 
from Dharmacon (USA). Cells were seeded into 1% gelatin-coated 
6-well plate and induced the transfection with either siDRP1 or 
scRNA using Lipofectamine RNAiMAX reagent (Thermo Fisher 
Scientific Inc.) following manufacturer’s instruction. 6 h after 
transfection, media was replaced with EGM-2 culture media. 
Further experiment was conducted 24-48 h after transfection.
Western blot
Human EPCs were lysed with Pro-prep (iNtRON biotechnol-
ogy, Korea). Whole cell lysates (25 mg) were separated by either 
8% or 15% SDS-PAGE, after which membranes were blocked 
with 5% skim milk for 1 h at 25°C. Membranes were probed with 
specific antibodies, and proteins of interest were visualized with 
HRP-conjugated secondary antibodies (Thermo Fisher Scientific 
Inc., MA, USA) and Luminata Crescendo HRP substrates (Milli-
pore, MA, USA). Primary antibodies against mouse anti-HIF-1A 
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Fig. 1. Hypoxia enhances EPC bioactivities. (A) Human EPCs were incubated under 1% O2 hypoxic or 20% O2 for 24 h. The migration assay was 
performed with a Boyden chamber. Cell migration was visualized by microscopy (magnification 200×). (B) Quantification of the number of migrating 
cells. Values represent mean±SEM. Experiments were performed in triplicates. **p<0.01. (C) Invasion assays was conducted with or without hypoxia in 
EPCs. (D) Quantification of invading cells. Values represent mean±SEM. Experiments were performed in triplicates. *p<0.05. (E) Representative images 
of hypoxia-induced tube formation in EPCs. EPCs were cultured on Matrigel GFR under normal or hypoxic conditions for 18 h. (F) Quantification of 
total tube length was performed using the Image J software. Experiments were conducted in triplicates. **p<0.01, as compared with that of control. (G) 
EPCs surface marker expression analyzed by flow cytometry. 
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(1:1000), mouse anti-DLP1 (1:1000, all above from BD Bioscienc-
es, NJ, USA), rabbit anti-phospho-DRP1 (Ser616) (1:1000), rabbit 
anti-phospho-DRP1 (Ser637) (1:1000, Cell Signaling Technology, 
Inc., MA, USA), rabbit anti-Fis1 (1:1000), rabbit anti-OPA1 (1:1000, 
all above Abcam, Cambridge, UK), rabbit anti-MFN1 (1:1000), 
and mouse anti-beta-actin (1:2500, all above Santa Cruz Biotech-
nology, CA, USA) were used.
Cell migration and invasion 
Human EPC migration assays was performed using 8 mm-pore 
transwell inserts (Corning Inc., MA, USA). For migration assays, 
2×105/ml cells were suspended in EBM-2 medium; 100 ml (20 000 
cells) cell suspension was added into the upper chamber, and 500 
ml EGM-2 media was placed in the lower chamber. For invasion 
assays, 50000 cells were seeded in Matrigel-coated transwell in-
serts (BD Biosciences, NJ, USA). After 24 h of incubation under 
normal or hypoxic conditions (1% O2), cells were fixed with 4% 
paraformaldehyde for 10 min, followed by staining with 0.5% 
crystal violet in 25% methanol for 30 min at 25°C. Cell migration 
and invasion were visualized with a Zeiss Axio Imager M2 opti-
cal microscope (Zeiss, Munchi, Germany), and cell counting was 
conducted with the Image J software.
Tube formation
Matrigel growth factor reduced (GFR) Basement Membrane 
Matrix (100 ml) (Corning Inc., MA, USA) was placed into 96-
well plates, and was incubated at 37°C and 5% CO2 for 1 h. Then, 
1×104 cells were seeded under normal or hypoxic conditions. 
Tube formation was observed for 6-18 h. In inhibition experi-
ments, cells were pre-treated with 12.5 mM Mdivi-1 for 24 h prior 
to tube formation. Total tube length was quantified using the Im-
age J software.
FACS analysis
Cells were suspended in FACS buffer (1% FBS, 2 mM EDTA in 
Fig. 2. Hypoxia-induced mitochondrial 
fission in EPCs. (A) Human EPCs were 
cultured under hypoxia or normoxia 
for 24 h, and mitochondrial fission was 
observed using confocal microscopy. 
TOM20 was used as a mitochondrial 
marker, and nuclei were stained with 
DAPI. The white square represents mag-
nification, as shown in the bottom panel. 
Scale bar=10 mm. (B) Hypoxia time-
dependent mitochondrial dynamics-
related gene expression was determined 
via immunoblot. EPCs were incubated 
under 1% O2 hypoxia or normoxia for the 
indicated time, and cells were harvested. 
Total DRP1, pDRP1 (S616), pDRP1 (S637), 
were used as mitochondrial fission mark-
ers, and OPA1, MFN1 were used as the 
markers of mitochondrial fusion, HIF-
1A was used as a hypoxic marker, and b-
actin was used for loading control. (C) 
Quantification of pDRP1 (S637) expres-
sion was attenuated during hypoxia. 
Three independent experiment were 
performed to statistical analysis. *p<0.05.
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PBS) and stained with specific antibodies including FITC-conju-
gated anti-CD34, APC-conjugated CXCR, Alexa Fluor 647-con-
jugated CD31, PE-conjugated KDR (all from BD Biosciences, NJ, 
USA), and APC-conjugated c-kit (Miltenyi Biotec, Germany). All 
antibodies were diluted 1:100; cells were incubated in primary an-
tibodies for 30 min at 4°C. After cells were washed twice with cold 
PBS, they were resuspended and analyzed with flow cytometry. 
Immunofluorescence and confocal microscopy
Human EPCs were seeded at a density of 4×104 cells/ml in 1% 
gelatin-coated cover glass. After 24 h, untreated or Mdivi-1 treat-
ed cells were cultured in either normal or 1% O2 for 24 h. Cells 
were then fixed with 4% paraformaldehyde for 15 min, and were 
permeabilized with 0.25% PBST for 10 min at room temperature. 
Unspecific binding was blocked (1% BSA in PBST) for 1 h at 
room temperature, followed by staining with mouse anti-Tom20 
antibody (1:100, Santa Cruz, CA, USA) at 4°C overnight. 
Statistical analysis
All data were presented as mean±standard error of mean (SEM). 
Descriptive statistics were analyzed using the GraphPad Prism 5 
software (GraphPad Software Inc., La Jolla, CA). We used Student’s 
unpaired t-tests for comparison between two groups. p<0.05 was 
the accepted value for statistical significance.
RESULTS
Hypoxia induces EPC bioactivities
To confirm the effect of hypoxia on EPCs bioactivities, we per-
formed angiogenic functional studies such as migration, invasion, 
and tube formation assays. Results indicated that hypoxia increase 
cell migration and invasion by 1.7- and 1.4- fold, respectively (Figs. 
1A-D). Similarly, cells under hypoxic conditions showed greater 
Fig. 3. DRP1-dependent mitochondrial fission in EPCs. (A, B) EPCs were treated with Mdivi-1 for 24 h with serially diluted Mdivi-1 (0-100 mM) in full (A) 
or starvation (B) media. Cell viability was analyzed and quantified using the CCK-8 assay. Values were normalized to negative control. All experiments 
were performed in at least triplicates. **p<0.01, ***p<0.001. (C) Cells were treated with 12.5 mM Mdivi-1, and cultured at 1% O2 for 24 h. Mitochondrial 
morphology was observed using confocal microscopy. White square indicates magnification, as shown in bottom panels. Scale bar=10 mm. TOM20 
was used for mitochondrial staining, and DAPI was used for nuclear staining.
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ability to form tubes as compared to that of control, which is an 
indicator of endothelial cell differentiation (Figs. 1E and F). To as-
sess whether hypoxia increases EPC population, we evaluated the 
expression of EPC surface markers such as CD31, KDR (VEGFR), 
c-kit, CXCR4, and CD34 using flow cytometry. No significant 
change was observed between normal and hypoxic conditions. 
Cells that were double positive for CXCR4, a known for migration 
marker, and CD34, a marker of EPC, were increased approxi-
Fig. 4. Mdivi-1 inhibits EPCs bioactivities under hypoxic condition. (A) EPCs were pre-treated with 12.5 mM Mdivi-1 for 24 h. Cells were seeded 
into the upper chamber with or without hypoxia for an additional 24 h. (B) Mdivi-1 pre-treated and untreated cells were seeded into Matrigel-coated 
transwell, and were cultured under normoxia or hypoxia for 24 h. Representative image from three independent experiments is shown. (C, D) Migrat-
ing (C) and invading cells (D) were quantified using the Image J software. All experiments were performed in at least triplicates. *p<0.05, **p<0.01. (E) 
EPCs were pretreated with 12.5 mM Mdivi-1 for 24 h, then seeded into Matrigel to induce tube formation under normal or hypoxic conditions. Tube 
structure was observed at 18 h. (F) Total tube length was measured. All experiments were performed in triplicates. *p<0.05, NS, no significant.
Mitochondrial fission in EPC bioactivities
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Fig. 5. DRP1 silencing inhibits hypoxia-induced angiogenic function. (A) EPCs were transiently induced with DRP1 siRNA for 48 h. Cells were har-
vested and detected the expression of DRP1 to confirm silencing. DRP1 siRNA dose-dependent transduction showed decreased expression. (B) DRP1 
silencing cells were seeded into the upper chamber with or without hypoxia for 6 h. DRP1 silencing cells showed decreased cell migration ability with 
or without hypoxic condition. (C) DRP1 silencing cells were seeded into Matrigel-coated transwell, and incubated under normoxic or hypoxic condi-
tion for 24 h. (D, E) Migrating (D) and Invading cells (E) were quantified using the Image J software. All experiment were conducted in at least tripli-
cates. *p<0.05, **p<0.01. (F) DRP1 silencing attenuated the ability of tube formation in the hypoxic condition. Tube structure was observed at 18 h. (G) 
Total tube length was measured using the Image J software. All experiment were performed at least triplicates. *p<0.05.
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mately by 1.7-fold under hypoxic conditions (Fig. 1G). However, 
other markers such as c-kit, a known for stemness, and CD31, a 
marker of endothelial lineage, and KDR, a one of the marker of 
EPC, showed slightly change. Taken together, our results showed 
that hypoxia increases cell migration, invasion, and tube forma-
tion, but does not have an effect on the EPC population. 
Mitochondrial fission-related dynamics in EPCs is 
induced in response to hypoxic signals
Recently, it has been reported that mitochondrial dynamics is 
one of the essential mechanisms of hypoxic cell signaling. To ver-
ify the effect of hypoxia on the mitochondrial dynamics in EPCs, 
we firstly detect the mitochondrial dynamics using confocal 
microscopy. We observed that mitochondrial fission was induced 
under hypoxic condition (Fig. 2A). In addition, the expression of 
mitochondrial fission/fusion-related gene was changed (Fig. 2B). 
DRP1 is a key regulator of fission, and phosphorylation of DRP1 
at Ser616 is typically used as an active form of DRP1. Dephos-
phorylation at Ser637 on DRP1 is also known to accelerate fis-
sion. Based on our results, the expression of pDRP1 (Ser637), an 
inhibition marker of fission, was significantly decreased in under 
hypoxic conditions at time point 24 h (Fig. 2C). Unexpectedly, 
pDRP1 (Ser616) was decreased during hypoxia. Fis1 is an adaptor 
of DRP1, which retains DRP1 in the mitochondria to accelerate 
fission. We observed that 24 h post-hypoxia, the expression of 
Fis1 was slightly increased, similar pattern to pDRP1 (Ser637). 
The expression of MFN1, OPA1, the markers of mitochondrial fu-
sion, were also decreased. Taken together, we suggest that pDRP1 
(Ser637)/Fis1/MFN1/OPA1 orchestrate inducing mitochondrial 
fission under hypoxic condition. 
Specific inhibition of DRP1 blocks hypoxia-induced 
mitochondrial fission in EPCs
To confirm DRP1 is involved in hypoxia-induced mitochondri-
Fig. 6. Mitochondrial dynamics does not influence the expression of EPC surface markers. The effect of Mdivi-1 on the expression of EPCs sur-
face marker was observed using flow cytometry analysis. EPCs were cultured with or without 12.5 mM Mdivi-1 for 24 h under hypoxia or normoxia; 
expression of surface markers CD34 and C-kit/CD31/KDR/CXCR4 was analyzed.
Mitochondrial fission in EPC bioactivities
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al fission, we used Mdivi-1, a known specific inhibitor of DRP1. 
First, we determined the optimal concentration of Mdivi-1 using 
the CCK-8 cell viability assay. At concentrations above 25 mM, 
EPCs showed cytotoxicity and reduced cell viability. Therefore, 
the concentration of Mdivi-1 for our 24-h incubation experi-
ments was set at 12.5 mM (Figs. 3A and B) without cell toxicity. As 
expected, confocal microscopy data demonstrated that hypoxia-
induced mitochondrial fission was blocked by Mdivi-1 treatment 
(Fig. 3C). Therefore, we confirmed that hypoxia-induced mito-
chondrial fission is mediated by DRP1 in EPCs.
Specific inhibition of DRP1 reduces hypoxia-induced 
EPC bioactivities 
To validate the role of DRP1-mediated mitochondrial fission 
in hypoxia-induced EPCs bioactivities, we assessed migration, 
invasion, and tube formation using DRP1 siRNA and DRP1 
specific inhibitor. In the presence of Mdivi-1, hypoxia-induced 
cell migration was blocked by 2.8-fold change, and cell invasion 
also showed a trend for reduction with Mdivi-1 treatment (Figs. 
4A-D). In addition, the ability for tube formation was reduced 
during DRP1 inhibition under hypoxic conditions (Figs. 4E and 
F). To confirm the role of DRP1-mediated mitochondrial fission 
in EPC angiogenic function, we performed the DRP1 siRNA 
experiments. We first confirmed that DRP1 expression was dra-
matically decreased up to 90% (Fig. 5A). DRP1 silencing showed 
decreased cell migration in 1.7-fold change, and decreased in cell 
invasion by 2.1-fold change under hypoxia (Figs. 5B-E), similar 
pattern to Mdivi-1 treatment. The ability of tube formation also 
decreased in DRP1 silencing cells, therefore we demonstrated 
that DRP1-mediated mitochondrial fission is essential step for 
hypoxia-induced EPCs angiogenesis. As expected, no significant 
changes were observed in EPC surface markers with Mdivi-1 
treatment (Fig. 6). Collectively, these data indicated that DRP1 is 
essential in hypoxia-induced EPC migration, invasion, and tube 
formation, but does not play a role in expression of EPC surface 
markers. 
DISCUSSION
In this study, we demonstrated that key role of DRP1-mediated 
mitochondrial fission in hypoxia-induced EPCs bioactivities; 
this is supported by data from previous studies. We observed that 
hypoxia-induced mitochondrial fission occurs in EPCs, which is 
correlated with evidence from previous reports in neuronal cells, 
cardiomyocytes, and cancer cells [17,19,20]. In addition, phos-
phorylated DRP1-Ser637, a suppression marker for mitochondrial 
fission, was impaired in hypoxic conditions. This suggested that 
pDRP1-Ser637 is a key molecule that mediates hypoxia-induced 
mitochondrial dynamics in EPCs. Coordinately, the expression 
of MFN1, OPA1 also showed reduction, and Fis1 tends to slightly 
increase under hypoxic conditions. Finally, targeting for DRP1 
using Mdivi-1, a selective DRP1 inhibitor, and DRP1 siRNA, 
showed dramatically impaired EPC migration, invasion, and tube 
formation even under hypoxic conditions. Therefore, we suggest 
that modulation of mitochondrial fission could be key mecha-
nism for hypoxia-induced angiogenesis.
It is the first time to discover the role of hypoxia-induced mi-
tochondrial fission in EPC-mediated angiogenesis. While several 
studies have reported that ischemia reperfusion-induced mito-
chondrial fission is associated with decreased ROS production 
and apoptosis in neuronal cells and cardiomyocyte [15,16,21], 
little is known about the effect of mitochondrial dynamics on 
angiogenesis. As hypoxia is known to affect both angiogenesis 
and mitochondrial function, we examined that the effect of mito-
chondrial dynamics on angiogenesis [22]. In agreement with our 
results, Zhao et al. confirmed that DRP1 plays critical roles in cell 
migration and invasion in breast cancer under hypoxic condi-
tion [23]. They also observed reduced cell migration and invasion 
under Mdivi-1 treatment, similar pattern to our result (Fig. 4A). 
In endothelial cells (ECs), little is known about the relationship 
between mitochondrial dynamics and cellular function. Lin et 
al. reported that decreased DRP1 and mitochondrial fusion is 
involved in senescence, but not in hypoxia-induced angiogenesis 
[24]. They demonstrated that Mdivi-1 treatment decreases cell 
proliferation, oxygen consumption rate (OCR), and G2/M cell cy-
cle arrest via autophagic flux. However, the critical regulatory site 
for DRP1 phosphorylation during senescence remains unclear. In 
addition, Kashatus et al. reported that MAPK/Erk2/pDRP1 axis is 
critical for tumor growth [25]. They showed that targeting DRP1 
impaired tumor growth, and that phosphorylation of DRP1 at 
Ser616 is critical for tumor development. Therefore, these reports 
support our hypothesis that targeting of mitochondrial dynamics 
is an effective strategy that not only inhibits tumor growth, but 
also impairs angiogenesis at tumor sites. 
In our results, pDRP1 (Ser637) seems to be a key regulatory 
site rather than pDRP1 (Ser616). Unexpectedly, the expression 
of pDRP1 (Ser616) was slightly but not significantly decreased in 
hypoxia. The expression of MFN1, and OPA1 tends to decrease in 
hypoxia. We also observed the mitochondrial fission using confo-
cal microscopy (Fig. 2A). Taken together, pDRP1 (Ser637), Fis1, 
MFN1, and OPA1 coordinately induce the mitochondrial fission 
during hypoxic condition, except pDRP1 (Ser616). Maybe there 
are two possible reasons to describe the expression of pDRP1-
Ser616 in hypoxic condition. First, decreased expression of 
pDRP1-Ser637 maybe major factor to induce mitochondrial fis-
sion rather than pDRP1-Ser616 in EPC. The response to hypoxia 
maybe different dependent on cell types, so pDRP1-Ser637/OPA1/
MFN1 orchestrate inducing mitochondrial fission especially in 
EPC. Second, hypoxia-induced phosphorylation site of DRP1 is 
controversial, yet. Because upstream signaling of pDRP1-Ser616 
and pDRP1-Ser637 are different and complex. Kim et al. reported 
that decreased pDRP1-Ser637 induced by AKAP121/Siah2 axis 
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plays essential role for mitochondrial fission to adapt the hypoxic 
condition [26], whereas Marsboom et al. reported that HIF1A/
cyclin B1/CDK1 induce DRP1 phosphorylation at Ser616, which 
leads to mitochondrial fission and pulmonary arterial smooth 
muscle proliferation [27]. Taken together, our results showed that 
pDRP1-Ser637, OPA1, MFN1 induce the mitochondrial fission 
response to hypoxic condition, especially in EPCs.
However, there is a missing gap between mitochondrial dy-
namics and angiogenesis. To address the missing gap, there are 
several possible hypotheses such as energy depletion, autophagic 
flux, and subcellular redistribution. According to Zhao et al., they 
addressed the mitochondrial fission is benefit to redistribution 
of mitochondrial to lamellipodia, which is essential step for cell 
migration [23], whereas mitochondrial fusion block that process. 
Another hypothesis is mitochondrial fission-induced energy 
depletion leads to inhibit the cell migration and invasion. Silvia 
et al. reported that oligomycin A, an inhibitor of mitochondrial 
F1F0-ATPase, inhibit the cell migration, and invasion because of 
lack of energy source, even under the DRP1-induced mitochon-
drial fission [28]. The other possible hypothesis is mitochondrial 
fission is involved in autophagic flux. Mdivi-1 treatment induced 
premature senescence and impaired angiogenic function by sup-
pressing autophagic flux. In contrast aberrant DRP1 expression 
restored autophagic flux and angiogenic function [24]. To address 
the precise mechanism of mitochondrial fission in EPC-mediated 
angiogenesis, further experiment is required. 
Mdivi-1, a selective DRP1 inhibitor, has been reported to be a 
potential therapeutic target for cancer due to its anti-cancer effect 
[29]. Previous studies generally used 50 mM Mdivi-1 for treat-
ment in cancer cells (IC50=50 mM) [30]. However, the sensitivity 
of EPCs to Mdivi-1 was four times higher as compared with that 
of cancer cells (Figs. 3A and B). According to our results, a dose 
of 12.5 mM Mdivi-1 exerted no significant effect on EPC viability, 
with or without serum starvation. To minimize cell toxicity, 12.5 
mM Mdivi-1 was used for further studies. We investigated the 
effect of Mdivi-1 on EPC bioactivities, namely, cell migration, 
invasion, and tube formation under hypoxic condition. Mdivi-1 
treatment showed significantly decreased migration, inva-
sion, and tube formation under hypoxia condition. That results 
showed similar pattern to DRP1 silencing experiment. Therefore, 
we suggest that targeting of DRP1 could be effective in preventing 
angiogenesis. However, we did not observe any significant effect 
of Mdivi-1 on EPC surface marker expression. While a slight 
change was detected, it was not sufficient to affect cell migration, 
invasion, and tube formation. Therefore, we confirmed that regu-
lation of mitochondrial fission-fusion affects EPC bioactivities, 
but not the population of the EPC. 
Taken together, we have presented a new perspective in cancer 
therapy, and have demonstrated that mitochondrial dynamics 
plays an important role in tumor angiogenesis. Furthermore, 
we suggest that specific modulation of mitochondrial dynamics 
under hypoxic conditions can be used as a potential therapeutic 
strategy in tumor angiogenesis.
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